[Skip to Content]
[Skip to Content Landing]
Views 401
Citations 0
Comment & Response
August 27, 2014

Bioprosthetic Valves for Transcatheter Aortic Valve Replacement

Author Affiliations
  • 1Division of Cardiology, Ferrarotto Hospital, University of Catania, Catania, Italy
JAMA. 2014;312(8):843-844. doi:10.1001/jama.2014.8359

To the Editor Dr Abdel-Wahab and colleagues1 reported a head-to-head comparison between currently available bioprostheses for transcatheter aortic valve replacement (TAVR). In the Comparison of Transcatheter Heart Valves in High Risk Patients With Severe Aortic Stenosis: Medtronic CoreValve vs Edwards SAPIEN XT (CHOICE) trial, a higher rate of device success was obtained with a balloon-expandable prosthesis than with a self-expanding prosthesis. This finding was partly driven by “a lower frequency of residual more-than-mild paravalvular aortic regurgitation. . . .” However, we believe that some limitations hamper this interpretation, particularly with regard to the assessment of postprocedural paravalvular regurgitation.